Effects of desvenlafaxine: A Synthesis of Findings from 24 Studies

  1. Home
  2. Effects of desvenlafaxine
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of desvenlafaxine: A Synthesis of Findings from 24 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of desvenlafaxine: A Synthesis of Findings from 24 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) used to treat depression. Studies have shown that desvenlafaxine is effective in treating major depressive disorder (MDD) and is non-inferior to another SNRI, duloxetine. 6 In addition, desvenlafaxine may also be effective in treating persistent depressive disorder (PDD), a form of depression that does not respond well to traditional treatments. 12 Desvenlafaxine can also be used as an anticonvulsant drug and can modulate brain monoamine and oxidative stress in mice. 1 Desvenlafaxine has been shown to have some protective effects against the effects of cuprizone-induced demyelination in mice, a model of multiple sclerosis. 21 However, desvenlafaxine can also have some adverse effects such as nausea, vomiting, and sexual dysfunction. 8 Additionally, desvenlafaxine may affect brain development in pregnant rats and their fetuses, highlighting the need to carefully consider its use during pregnancy. 13

Benefits and Risks

Benefits Summary

Desvenlafaxine is an effective treatment for MDD and is non-inferior to another SNRI, duloxetine. 6 It may also be effective in treating PDD and has protective effects against the effects of cuprizone-induced demyelination. 12 21

Risks Summary

Desvenlafaxine can cause side effects such as nausea, vomiting, and sexual dysfunction. 8 It is important to note that desvenlafaxine may affect brain development in pregnant rats and their fetuses. 13

Comparison Between Studies

Similarities Between Studies

Many studies have shown that desvenlafaxine is effective in treating MDD. 8 These studies have also indicated that desvenlafaxine is non-inferior to other SNRIs, such as duloxetine. 6

Differences Between Studies

The specific types of depression that desvenlafaxine is most effective for, as well as the strength of its effects, can vary between studies. 12 Additionally, the frequency and severity of side effects can also differ between studies. 8

Consistency and Contradictions of Results

Overall, the results of the studies are consistent in showing that desvenlafaxine is effective in treating MDD. 8 However, there are some differences in the types of depression that desvenlafaxine is most effective for, as well as the strength of its effects and the frequency and severity of side effects. 12 Further research is needed to clarify these inconsistencies.

Practical Implications

Desvenlafaxine is a potentially effective treatment for depression. 8 However, it is important to speak to a doctor before taking desvenlafaxine, as it can cause side effects. 8 It is also important to be aware that desvenlafaxine may not be appropriate for everyone, especially pregnant women. 13 It is crucial to discuss any concerns with your doctor and to consider both medication and psychotherapy in treating depression. 14

Limitations of Current Research

Many of the studies on desvenlafaxine are small, and larger studies are needed to confirm the findings. 8 Additionally, the mechanisms by which desvenlafaxine exerts its effects are not fully understood. 12

Future Research Directions

Large-scale studies are needed to further evaluate the efficacy and safety of desvenlafaxine. 8 Additionally, research is needed to understand the mechanisms by which desvenlafaxine exerts its effects. 12

Conclusion

Desvenlafaxine is a potentially effective treatment for depression, but it is not a cure-all. 8 It is important to discuss your options with your doctor to determine if desvenlafaxine is right for you. 8 Remember that treatment for depression often includes both medication and psychotherapy. 14 If you are struggling with depression, know that help is available. Reach out to your doctor or a mental health professional.

Literature analysis of 24 papers
Positive Content
16
Neutral Content
2
Negative Content
6
Article Type
3
3
1
3
22
2.

Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis.

Author: KatzmanMartin A, WangXuemei, WajsbrotDalia B, BoucherMatthieu

Depression symptom reduction

Desvenlafaxine effectively improved symptom clusters in major depressive disorder compared to placebo. Early improvement in symptom clusters was associated with symptomatic or functional remission at week 8.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

A randomized controlled trial of desvenlafaxine-induced structural brain changes in the treatment of persistent depressive disorder.

Author: BansalRavi, HellersteinDavid J, SawardekarSiddhant, ChenYing, PetersonBradley S

Treats depression

This study investigated the effects of desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor, on cortical thickness in patients with Persistent Depressive Disorder (PDD). While no significant treatment-by-time effects were observed, baseline cortical thickness may predict treatment response.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder.

Author: ZhaoQian, FuBingbing, LyuNan, XuXiangdong, HuangGuangbiao, TanYunlong, XuXiufeng, ZhangXuehua, WangXueyi, WangZhiqiang, LiKeqing, HuZhenYu, LiHengfen, HeHongbo, LiShuang, ZhaoJingyuan, HeRuifeng, GuoHua, LiYi, LiLehua, YangChuang, ZouShaohong, WeiBo, WangWenqiang, ChenCe, LuZheng, HeShunqiang, WangQian, ZhaoJinghua, PanXiaoyue, PanZhenyu, LiJunqing, WangGang

Major depressive disorder treatment
Non-inferior efficacy

Desvenlafaxine and duloxetine are both medications used to treat major depressive disorder (MDD). This study aimed to compare the effectiveness of desvenlafaxine extended-release (XL) to duloxetine in patients with MDD.

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

A Comprehensive Review on Postpartum Depression.

Author: SuryawanshiOm, PajaiSandhya

Early PPD diagnosis
PPD management
Methyldopa-related depression
PPD impact on child

Postpartum depression (PPD) is a common psychological condition affecting mothers after childbirth. This article explores the risk factors, pathophysiology, diagnosis, and treatment of PPD, including the potential role of methyldopa in its development.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.

Author: KishiTaro, IkutaToshikazu, SakumaKenji, OkuyaMakoto, HatanoMasakazu, MatsudaYuki, IwataNakao

MDD treatment
Relapse prevention
Antidepressant side effects
Major depressive disorder

Desvenlafaxine, paroxetine, venlafaxine, and vortioxetine were found to be effective in preventing relapse in patients with major depressive disorder (MDD). These antidepressants had acceptable tolerability, with lower discontinuation rates than placebo.

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Intracranial hemorrhage after a single dose of Yohimbine in a chronic user of clonidine.

Author: HodappBenjamin, HaggertyAdam, FeldmanRyan, TimpeJoshua

ICH

This abstract reports a case of intracranial hemorrhage in a female patient after ingesting yohimbine, a supplement often used for libido and weight loss. Yohimbine toxicity causes a sympathomimetic syndrome.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

10.

Anxiolytic Effect of Carvedilol in Chronic Unpredictable Stress Model.

Author: de SousaCaren Nádia Soares, da Silva MedeirosIngridy, VasconcelosGermana Silva, de AquinoGabriel Ângelo, FilhoFrancisco Maurício Sales Cysne, de AlmeidaJamily Cunha, AlvesAna Paula Negreiros Nunes, MacêdoDanielle S, LealLuzia Kalyne Almeida Moreira, VasconcelosSilvânia Maria Mendes

Anxiolytic effect

This study evaluated the anxiolytic-like effects of carvedilol (CVD), a drug with antioxidant properties, in animals exposed to chronic unpredictable stress (CUS). CVD demonstrated anxiolytic effects, reducing anxiety-like behaviors and reversing CUS-induced alterations in adrenal gland size and inflammatory markers.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

Case Report: Possible Serotonin Syndrome in a Patient Taking Kratom and Multiple Serotonergic Agents.

Author: EudaleySarah T, BrooksShelby P, HamiltonLeslie A

Serotonin syndrome

Kratom, an herbal supplement, is used to self-treat anxiety and depression. Kratom inhibits cytochrome P450 isozymes, which can alter the metabolism of prescription medications. This case report suggests that kratom use may cause serotonin syndrome when combined with psychotropic medications.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

14.

Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer.

Author: BatesNicole, BelloJennifer K, Osazuwa-PetersNosayaba, SullivanMark D, ScherrerJeffrey F

Depression screening
Pain management

This paper provides recommendations for managing depression in cancer patients on long-term opioid therapy, including screening before and during treatment, and exploring various treatment options, including medication and psychotherapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

15.

Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials.

Author: TurnerErick H, CiprianiAndrea, FurukawaToshi A, SalantiGeorgia, de VriesYmkje Anna

Reporting bias

This study assessed the reporting bias in the published literature on antidepressant drugs by comparing published findings to information from FDA drug approval packages. The study found that the published literature tended to overstate the efficacy of antidepressant drugs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.

Language : English

18.

Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: A real-world study using the WHO pharmacovigilance database.

Author: QuilichiniJean-Baptiste, RevetAlexis, GarciaPhilippe, BouquiéRégis, HamardJacques, YrondiAntoine, MontastrucFrançois

Withdrawal syndrome

Short half-life antidepressants are associated with an increased risk of reporting withdrawal syndrome compared to long half-life antidepressants. Among the most common antidepressants, paroxetine and serotonin-noradrenaline reuptake inhibitors are associated with a greater risk of reporting withdrawal syndrome, while agomelatine and vortioxetine present a lower risk.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

21.

Effects of Venlafaxine, Risperidone and Febuxostat on Cuprizone-Induced Demyelination, Behavioral Deficits and Oxidative Stress.

Author: MihaiDragos Paul, UngurianuAnca, CiotuCosmin I, FischerMichael J M, OlaruOctavian Tudorel, NitulescuGeorge Mihai, AndreiCorina, ZbarceaCristina Elena, ZanfirescuAnca, SeremetOana Cristina, ChiritaCornel, NegresSimona

Cold sensitivity
Motor performance
Oxidative stress

This study investigated the effects of venlafaxine, risperidone, and febuxostat in a cuprizone mouse model of multiple sclerosis (MS). The study found that all three drugs offered some protection against the effects of demyelination, with venlafaxine and risperidone showing significant improvements in motor performance and cold sensitivity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

22.

Lack of an Effect of Supratherapeutic Dose of Venlafaxine on Cardiac Repolarization in Healthy Subjects.

Author: AbbasRichat, RileySteve, NepalSunil, BachinskyMary, LeeKimberly C, ChappellPhillip B, DamleBharat

Lack of QTc prolongation
Venlafaxine safety

This study found that supratherapeutic doses of venlafaxine did not significantly prolong the QT interval in healthy adults, suggesting that venlafaxine is unlikely to increase the risk of cardiac arrhythmias. The study also found that venlafaxine was safe and well tolerated at supratherapeutic doses.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

23.

Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses.

Author: JuulSophie, SiddiquiFaiza, BarbateskovicMarija, JørgensenCaroline Kamp, HengartnerMichael Pascal, KirschIrving, GluudChristian, JakobsenJanus Christian

Depression treatment
Harmful effects

This review aims to evaluate the beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.